Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $2.2 million.

  • Insight Molecular Diagnostics' Accumulated Expenses rose 16.89% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 16.89%. This contributed to the annual value of $1.9 million for FY2024, which is 17.59% up from last year.
  • Insight Molecular Diagnostics' Accumulated Expenses amounted to $2.2 million in Q3 2025, which was up 52.71% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Accumulated Expenses registered a high of $4.1 million during Q3 2022, and its lowest value of $1.3 million during Q2 2023.
  • In the last 3 years, Insight Molecular Diagnostics' Accumulated Expenses had a median value of $1.8 million in 2023 and averaged $1.8 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Accumulated Expenses spiked by 138.29% in 2021, and later tumbled by 57.66% in 2023.
  • Insight Molecular Diagnostics' Accumulated Expenses (Quarterly) stood at $2.8 million in 2021, then decreased by 28.48% to $2.0 million in 2022, then decreased by 18.45% to $1.6 million in 2023, then grew by 17.59% to $1.9 million in 2024, then grew by 16.89% to $2.2 million in 2025.
  • Its Accumulated Expenses stands at $2.2 million for Q3 2025, versus $1.5 million for Q2 2025 and $2.5 million for Q1 2025.